Shield Therapeutics PLC Grant of Share Awards (6727J)
September 13 2016 - 3:25AM
UK Regulatory
TIDMSTX TIDMSTXW
RNS Number : 6727J
Shield Therapeutics PLC
13 September 2016
Shield Therapeutics plc
("Shield" or the "Company")
Grant of Share Awards
London, UK, 13(th) September 2016. Shield Therapeutics plc
(LSE:STX), a specialty pharmaceutical company focused on secondary
care, announces that, following approval at the AGM on 4(th) August
2016, it has granted awards in the form of options over ordinary
shares in the capital of the Company ("Award Shares") to the
following executives under its Long Term Incentive Plan
("LTIP").
Carl Sterritt: Director 92,767
Richard Jones: Director 67,610
Paul Steckler PDMR 58,176
Angela Hildreth PDMR 34,591
In total awards have now been granted over 2,026,725 shares
under the LTIP. The exercise price per Award Share is 1.5 pence and
awards are exercisable between February 2019 and February 2026,
subject to applicable performance conditions having been satisfied.
The grant of awards is part of the Company's long-term incentive
arrangements designed to directly align the interest of the
shareholders and executives.
The Company's LTIP was adopted by the Board on 12th February
2016. The LTIP provides for awards of ordinary shares to be made to
eligible employees. The arrangements are described more fully in
the Admission Document, a copy of which is available on the
Company's website (www.shieldtherapeutics.com).
-Ends-
For further information please contact:
Shield Therapeutics plc +44 (0)191 511 8507
Carl Sterritt, Chief Executive
Officer
Richard Jones, Chief Financial
Officer
Nominated Adviser and Sole
Broker
Liberum Capital Limited
Christopher Britton
Steve Pearce
Jamil Miah +44 (0)20 3100 2222
Financial PR Advisor +44 (0)203 709 5700
Consilium Strategic Communications shieldtherapeutics@consilium-comms.com
Mary-Jane Elliott
Matthew Neal
Lindsey Neville
Hendrik Thys
About Shield Therapeutics plc
Shield Therapeutics is a specialty pharmaceutical company
focused on the commercialisation and development of late-stage,
hospital-focused pharmaceuticals which address areas of unmet
medical need. The Company has a marketed product, Feraccru(R), for
the treatment of iron deficiency anaemia (IDA) which has exclusive
IP rights until 2034. In addition, the Company is developing PT20,
a late-stage pharmaceutical for the treatment of systemic phosphate
accumulation (hyperphosphatemia). Shield Therapeutics,
headquartered in London, is listed on LSE's AIM under the ticker
STX. For more information please visit
www.shieldtherapeutics.com.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the person discharging managerial
responsibilities/person closely associated
--- ------------------------------------------------------------------
a) Name Carl Sterritt: Director / PDMR
Richard Jones: Director / PDMR
Paul Steckler PDMR
Angela Hildreth PDMR
--- ------------------------- ---------------------------------------
2 Reason for the notification
--- ------------------------------------------------------------------
a) Position/status All PDMRs of Shield Therapeutics
--- ------------------------- ---------------------------------------
b) Initial Initial Notification
notification/
Amendment
--- ------------------------- ---------------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform,
auctioneer or auction monitor
--- ------------------------------------------------------------------
a) Name Shield Therapeutics plc
--- ------------------------- ---------------------------------------
b) LEI n/a
--- ------------------------- ---------------------------------------
4 Details of the transaction(s): section
to be repeated for (i) each type of
instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place
where transactions have been conducted
--- ------------------------------------------------------------------
a) Description Option over ordinary shares
of the of 1.5p each in the capital
financial of the Company
instrument,
type of
instrument
Identification ISIN of Ordinary Shares: GB00BYV81293
code
--- ------------------------- ---------------------------------------
b) Nature Grant of Options over ordinary
of the shares in accordance with the
transaction Company's Long Term Incentive
Plan
--- ------------------------- ---------------------------------------
c) Price(s) Exercise price: 1.5p
and volume(s)
Volumes:
Carl Sterritt: 92,767
Richard Jones: 67,610
Paul Steckler 58,176
Angela Hildreth 34,591
--- ------------------------- ---------------------------------------
d) Aggregated
information
* Aggregated volume 253,144
Exercise price: 1.5p
* Price
--- ------------------------- ---------------------------------------
e) Date of 12 September 2016
the transaction
--- ------------------------- ---------------------------------------
f) Place Outside a trading venue
of the
transaction
--- ------------------------- ---------------------------------------
Name of authorised official of issuer responsible for making
notification.
Richard Jones
CFO and Company Secretary to Shield Therapeutics plc
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHLJMPTMBTBMBF
(END) Dow Jones Newswires
September 13, 2016 04:25 ET (08:25 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Apr 2024 to May 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From May 2023 to May 2024